essential oils phytochemicals used for treatment mrsa diabetic foot tb

8/14/2019 Essential Oils Phytochemicals Used for Treatment MRSA Diabetic Foot TB

1/23

Phytochemicals

australias gift to the world

Eugene Sherry OR Design Unit, Univ Sydney

Patrick H Warnke Univ Kiel, Germany


2/23

Univ. of Kiel, and Univ.Sydney


3/23

DAY

ONE

DAY

12

DAY

28

52 yo Female/SAm/TA repair withwound breakdown at 3 monthsPT used daily


4/23

MRSA FACTSMRSA infection rates in Europe and USA are as high as 30% in ICU. [Geldner G,Ruoff M, Hoffman H.-J, Georgieff M, Wiedeck H, Cost Analysis - MRSA - ICUDepartment of Anaesthesiology, University of Ulm, Germany]Average monthly cost of MRSA patient = 9408 EURO[Geldner G, Ruoff M,Hoffman H.-J, Georgieff M, Wiedeck H, Cost Analysis - MRSA - ICU Department of Anaesthesiology, University of Ulm, Germany]

New York City Hospitals cost per MRSA patient up to US $35,300 [Rubin RJ,Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A, The EconomicImpact of Staphylococcus aureus Infection in New York City Hospitals, EmergingInfectious Diseases, Vol 5(1)1999]

The additional cost imposed on the US health system annually by antibioticresistance has been estimated to range between US $100 million and US $30 billion.[Hellinger WC, Confronting the problem of Increasing Antibiotic Resistance, South

Med J 93(9): 842-848, 2000][Phelps CE: Bug/drug resistance. Sometimes less ismore. Med Care 1989; 27:194-203]

Australia-(approx) (AUD)$4B@ year; 40,000 joints @ year; 300 hospitalsResistance has developed and increasing in Vancomycin "the drug of last resort",presenting Doctors with no other antibiotics to treat infection. [Gilliland KK, FloresPA, Gordon SM, Vancomycin-Resistant Staph: Epidemiology and TherapeuticOptions; Infect Med 17(4):289-298, 2000]

Vancomycin Hcl has many side effects including difficulty breathing, weakness,Ototoxicity, Tinnitus and drug induced Nephrotoxicity.[First DataBank, USA]


5/23

HISS study

Study of Hospital Acquired Infections CABG 1.3% Vascular surgery 7.3% Hip prosthesis 0.5% Knee prosthesis 9.8%

LSCS 2.3% Colorectal 12.7%


6/23

Extrapolations from HISS MRSA data to NSWSurgical Patients

Type of Hospitals Total Number of Infected Surgical Patients / Surgical

separations for 1 year Principal Referral 355/ 126,707 Major Metropolitan 71/50855 Major Non-Metropolitan 7/33093 Total 433 / 210655 surgical patients

= 2.1 per 1000 surgical patients

Mean cost 1

per patient $32,362 Total Cost for NSW Principal referral, Major Metropolitan and Non-metropolitan

hospitals $14 million per year .National Surveillance of healthcare Associated Infection in Australia: A Report

to the commonwealth Department of health and Aged Care prepared by the Expert

Working Group of Australian Infection


7/23

Sustainability science within a divided world(Sustainability Science RW Kates et al, Science 292 27 April, 2001 p641-2)

North Old,rich millions

Affluence Global people Resource surpluses Technological knowledge Theory-driven research

South Young,poor billions

Poverty Local people Resource shortages

Impacts of climatechanges

Traditional knowledge Action-driven research


8/23

The AIDS problem is so devastating that what you want

is answers now and understanding later(Maurive Hilleman,veteran vaccinologist. Science 4 May 2001 p 862)

Out of Africa (old)- Africa is home to most every infectious agent that has ever plagued

humans. (John Cohen. Shots in the Dark. Science 4 May 2001 p 862)

From Australia (new)- Blue Mountains. National Park. One Million Hectares Eucalyptus ? Place of Healing.


9/23

Phytochemicals

Eucalyptus Oil- KLONEMAX

Tea-Tree Oil-

Combination


10/23

ONE SUCH PRODUCT : Polytoxinol

-antimicrobial liquid,-complex formulation of plant extracts,

-strongly bactericidal in vitro against a broad range of aerobicbacteria,including methicillin resistant Staphylococcus aureus(MRSA),

- other constituents that are anti-inflammatory and promote healing(product information, listed in MINS, p 312 Dec 2000 issue)

-TGA licensed-German Commission E approves internal use and steam

inhalation/American Herbal Products Assoc-class 2d safetyrating

-Licensed through the General Sale List in UK


11/23

Antisepsis history OW Holmes(19th C) Semmelweis,Vienna,

high maternal sepsisrate Lister(1827-12),

12/8/1865 sprayed

carbolic acid over wound during surgery

Sir W MacEwen Sir John

Charnley(1911-82) Florey,penicillin,huma

n trials 1941 2001 FAILURE of

antibiotics: onlyvancomycin/animaluse/synercid Nature 411

p 513 2001; ZYBOX lasted 12 mths


12/23

Activities of eucalyptus oil

-antibacterial-all bacteria, incl pseudomonas & MRSA. -antifungal, anti-mycosis. Candida, aspergillus( HIV) -anti-inflammatory

-anti-cancer. Skin and pulm tumours in mice. -liverprotective -anti-plaque -pain reliever

see handout(documented in literature/PubMed)


13/23

Other plant derivatives

Aspirin(bark of willow tree)

Digitalis(foxglove)

KloneMax.


14/23

Administration Liquid(spray) Cream

SW-Inhaler S(inhalational):Pneumocystiscarinnii (HIV and Immunodefic) &Pseudomonas aeruginosa (HIV, CysticFibrosis).Patented Product available.

beads(calcium crystal carrier)


15/23

(possible) KloneMax application via SW-Inhaler S in respiratory tract infections

Warnke PH(1), Sherry E(2), Polzhofer GK(3), von Engeln K(4),Schuenemann H(5)

1: Dept of Oral- and Maxillofacial Surgery, University of Kiel,Germany2: Dept of Orthopedic Surgery, University of Sydney, Australia3: Dept of Dermatology, University of Kiel, Germany4: Dept of Otorhinolaryngology, Head- and Neck Surgery, Univ of

Heidelberg,Germany5: Cosmas-Pharmacie, Barssel, Germany


16/23

biofilm, KM is a slimebuster

Bacterial grow on surfaces in slimymicrobial cities, 1000x more resistant

KM can ?penetrate these films,unlike other antimicrobial agents(nature 408 16 nov2000 p284-6)

K+-membrane leakage in E.coli


17/23

Vancomycin-resistant staph

aureus reported in Australia

MJA 175 5 Nov 2001 p 480-483


18/23

TB FACTS TB infects 2 billion people worldwide [Butler D, Consortium Aims to

Kickstart TB Research, Macmillan Publishers 2000]Resistance to drugs for the treatment TB is increasing [Hellinger WC,Confronting the problem of Increasing Antibiotic Resistance, South Med J93(9): 842-848, 2000][Pablos-Mendez A, Raviglione MC, Laszlo A, et al:Global surveillance for antituberculosis-drug resistance 1994-1997. WHO -International Union against Tuberculosis and Lung Disease Working Group

on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-1649]

There are 8 million new cases, and two million deaths each year from TB.[Butler D, Consortium Aims to Kickstart TB Research, Macmillan Publishers2000]

WHO Director-General, " it is high time to find new and more effectivedrugs"[Butler D, Consortium Aims to Kickstart TB Research, Macmillan

Publishers 2000]In 1998, it is estimated 10 million people died from Infectious diseases.[Weinstein RA, Talkpaper, 40 th Interscience Conference on AntimicrobialAgents & Chemotherapy, Medscape Inc.

No new drug has been developed for the treatment of TB for 30 years.

Treatment of TB involves many drugs and hospitalisation and high costs.


19/23

TB FACTS

TB infects 2 billion people worldwide [ Butler D, Consortium Aims to Kickstart TB Research, Macmillan Publishers 2000]

WHO estimates there will be 90 million new cases and 30million deaths by 2010, and if current infection rates andtreatment trends go unchanged, 70 million more peoplewill die between now and 2020. [New drug eases TB treatment, American Medical News, Vol.41, No. 28, July 27, 1998]

South-East Asia constitutes the biggest burden in TBcontrol worldwide [World TB Day 2001, Fact Sheet, www.stoptb.org ]Treatment costs around US $2500 per patient, rising toUS $250,000 in multi drug resistant TB, with the overall

potential cost of lost productivity due to TB is in the order of 4%-7% of GDP(same ref).
http://www.stoptb.org/http://www.stoptb.org/http://www.stoptb.org/http://www.stoptb.org/


20/23

TB facts ctd

Resistance to drugs for the treatment TB is increasing. [Hellinger WC, Confronting the problem of Increasing Antibiotic Resistance,

South Med J 93(9): 842-848, 2000][Pablos-Mendez A, Raviglione MC, Laszlo A, et al: Global surveillance for antituberculosis-drug resistance 1994-1997. WHO -

International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl. J Med 1998; 338:1641-1649]

There are 8 million new cases, and two million deathseach year from TB. [Butler D, Consortium Aims to

Kickstart TB Research, Macmillan Publishers 2000

WHO Director-General, " it is high time to find new andmore effective drugs".

[Butler D, Consortium Aims to Kickstart TB Research,Macmillan Publishers 2000]


21/23

comment from AJIC, 3 July, 2001

> "This paper presents a provocativehypothesis that an oil extract of the

> Australian trees Eucalyptus globulus...,which is active against Mycobacteriumtuberculosis in vitro

> may be of value in the treatment of tuberculosis


22/23

KloneMax challengedagainst Mycobacterium terrae

Nov, 2001

10 ml product challenged with 1 ml M.terrae. At eachexposure time, 1 ml of mixture was subcultured into 99 mlneutraliser and plated out for surviving organisms. 0.1mlof the neutralised suspension was spread on pre-poured

plate,giving a final sensitivity level of < 1000 cfuM.terae/ml.


23/23

results

Contacttime

10 mins 20 mins 30 mins 40 mins

Day 14 1.2 x 10 6 5.4 x 10 5 2.0 x 10 5 8.0 x 10 3

RecoveryM.terrae 10%

essential oils phytochemicals used for treatment mrsa diabetic foot tb

Documents